Bifidobacterium spp: the promising Trojan Horse in the era of precision oncology.
Future Oncol
; 15(33): 3861-3876, 2019 Nov.
Article
em En
| MEDLINE
| ID: mdl-31668087
ABSTRACT
Selective delivery of therapeutic agents into solid tumors has been a major challenge impeding the achievement of long-term disease remission and cure. The need to develop alternative drug delivery routes to achieve higher drug concentration in tumor tissue, reduce unwanted off-target side effects and thus achieve greater therapeutic efficacy, has resulted in an explosive body of research. Bifidobacterium spp. are anaerobic, nonpathogenic, Gram-positive bacteria, commensal to the human gut that are a possible anticancer drug-delivery vehicle. In this review, we describe Bifidobacterium's microbiology, current clinical applications, overview of the preclinical work investigating Bifidobacterium's potential to deliver anticancer therapy, and review the different strategies used up to date. Finally, we discuss both current challenges and future prospects.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Bifidobacterium
/
Sistemas de Liberação de Medicamentos
/
Medicina de Precisão
/
Imunoterapia
/
Oncologia
/
Neoplasias
Tipo de estudo:
Prognostic_studies
Limite:
Animals
/
Humans
Idioma:
En
Revista:
Future Oncol
Ano de publicação:
2019
Tipo de documento:
Article
País de afiliação:
Estados Unidos